Microdialysis for assessing intratumoral drug disposition in brain cancers: A tool for rational drug development

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 12, 2010, Pages 1477-1491

  Blakeley, Jaishri ^a   Portnow, Jana ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

BBB; Brain cancer; Clinical trial; Drug delivery; Microdialysis; Pharmacodynamics; Pharmacokinetics; Tumor

Indexed keywords

CISPLATIN; DASATINIB; ERLOTINIB; GEFITINIB; METHOTREXATE; TEMOZOLOMIDE; TOPOTECAN;

AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TISSUE LEVEL; EXTRACELLULAR FLUID; GLIOBLASTOMA; GLIOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICRODIALYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIMARY TUMOR; REVIEW; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; EXTRACELLULAR FLUID; HUMANS; MICRODIALYSIS; TISSUE DISTRIBUTION;

EID: 78649303718     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2010.523420     Document Type: Review

References (132)

1. CBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in eighteen states in 2002-2006. Published by the central brain tumor registry of the United States, Hinsdale, IL. 2009-2010. Available from: www.cbtrus.org
2. Stupp R, Mason WP, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96
3. Merchant TE, Pollack IF, Loeffler JS. Brain tumors across the age spectrum: biology, therapy, and late effects. Semin Radiat Oncol 2010;20(1):58-66
4. Minniti G, Muni R, Lanzetta G, et al. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res 2009;29(12):5171-84
5. Omuro AM. Exploring multi-targeting strategies for the treatment of gliomas. Curr Opin Investig Drugs 2008;9(12):1287-95
6. Yung WK, Albright RE, Olson J, et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83(5):588-93
7. Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 2006;11(2):152-64
8. Dunbar E, Yachnis AT. Glioma diagnosis: immunohistochemistry and beyond. Adv Anat Pathol 2010;17(3):187-201
9. Burger PC, Heinz ER, Shibata T, Kleihues P. Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 1988;68(5):698-704
10. Salmaggi A, Boiardi A, Gelati M, et al. Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 2006;54(8):850-60
11. Leuraud P, Taillandier L, Medioni J, et al. Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations. Cancer Res 2004;64(13):4648-53
12. Bleau AM, Hambardzumyan D, Ozawa T, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009;4(3):226-35
13. Chua C, Zaiden N, Chong KH, et al. Characterization of a side population of astrocytoma cells in response to temozolomide. J Neurosurg 2008;109(5):856-66
14. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007;99(19):1441-54
15. Colvin OM, Friedman HS, Gamcsik MP, et al. Role of glutathione in cellular resistance to alkylating agents. Adv Enzyme Regul 1993;33:19-26
16. Siegelin MD, Plescia J, Raskett CM, et al. Global targeting of subcellular heat shock protein-90 networks for therapy of glioblastoma. Mol Cancer Ther 2010;9(6):1638-46
17. Hoelzinger DB, Demuth T, Berens ME. Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst 2007;99(21):1583-93
18. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
19. Netti PA, Baxter LT, Boucher Y, et al. Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res 1995;55(22):5451-8
20. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994;271(1):58-65
21. Zhang M, Aguilera D, Das C, et al. Measuring cytotoxicity: a new perspective on LC50. Anticancer Res 2007;27(1 A): 35-8
22. Wolff JE, Trilling T, Molenkamp G, et al. Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol 1999;125(8-9): 481-6
23. Blakeley J. Drug delivery to brain tumors. Curr Neurol Neurosci Rep 2008;8(3):235-41
24. Cecchelli R, Berezowski V, Lundquist S, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 2007;6(8):650-61
25. Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res 2007;24(9):1759-71
26. Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol 2000;2(1):45-59
27. Muldoon LL, Pagel MA, Kroll RA, et al. A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery. AJNR Am J Neuroradiol 1999;20(2):217-22
28. Colgan OC, Collins NT, Ferguson G, et al. Influence of basolateral condition on the regulation of brain microvascular endothelial tight junction properties and barrier function. Brain Res 2007;1193:84-92
29. Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5(3):219-34
30. Agarwal S, Sane R, Gallardo JL, et al. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther 2010;334(1):147-55
31. Chen Y, Agarwal S, Shaik NM, et al. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J Pharmacol Exp Ther 2009;330(3):956-63
32. Decleves X, Bihorel S, Debray M, et al. ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells. Pharmacol Res 2008;57(3):214-22
33. Nies AT, Jedlitschky G, Konig J, et al. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 2004;129(2):349-60
34. Warnke PC, Kopitzki K, Timmer J, Ostertag CB. Capillary physiology of human medulloblastoma: impact on chemotherapy. Cancer 2006;107(9):2223-7
35. Blakeley JO, Olson J, Grossman SA, et al.; New Approaches to Brain Tumor Therapy (NABTT) Consortium. Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. J Neurooncol 2009;91(1):51-8
36. Zunkeler B, Carson RE, Olson J, et al. Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg 1996;85(6):1056-65
37. de Lange EC, Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 2002;41(10):691-703
38. Blakeley JO, Laterra J. Neoplastic and paraneoplastic disorders. In: Irani D, editor, Cerebrospinal fluid in clinical practice. Volume 1. Saunders Elsevier, Philadephia, PA; 2009. p. 233
39. Jacobs S, McCully CL, Murphy RF, et al. Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates. Cancer Chemother Pharmacol 2010;65(5):817-24
40. Portnow J, Badie B, Chen M, et al. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res 2009;15(22):7092-8
41. Lovich MA, Edelman ER. Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo. Proc Natl Acad Sci USA 1999;96(20):11111-16
42. Clarke JL, Pao W, Wu N, et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010;99(2):283-6
43. Togashi Y, Masago K, Fukudo M, et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol 2010;5(7):950-5
44. Lassman AB, Rossi MR, Raizer JJ, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005;11(21):7841-50
45. Raizer JJ, Abrey LE, Lassman AB, et al.; North American Brain Tumor Consortium. A Phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 2010;12(1):95-103
46. Holdhoff M, Supko JG, Gallia GL, et al. Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J Neurooncol 2010;97(2):241-5
47. Razis E, Selviaridis P, Labropoulos S, et al. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res 2009;15(19):6258-66
48. Zamboni WC, Gervais AC, Egorin MJ, et al. Inter-and intratumoral disposition of platinum in solid tumors after administration of cisplatin. Clin Cancer Res 2002;8(9):2992-9
49. Zamboni WC, Houghton PJ, Hulstein JL, et al. Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemother Pharmacol 1999;43(4):269-76
50. Zamboni WC, Stewart CF, Cheshire PJ, et al. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. Clin Cancer Res 1998;4(3):743-53
51. Hutschala D, Kinstner C, Skhirtladze K, et al. The impact of perioperative atelectasis on antibiotic penetration into lung tissue: an in vivo microdialysis study. Intensive Care Med 2008;34(10):1827-34
52. Karjagin J, Lefeuvre S, Oselin K, et al. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther 2008;83(3):452-9
53. Zeitlinger BS, Zeitlinger M, Leitner I, et al. Clinical scoring system for the prediction of target site penetration of antimicrobials in patients with sepsis. Clin Pharmacokinet 2007;46(1):75-83
54. Bellmann R, Kuchling G, Dehghanyar P, et al. Tissue pharmacokinetics of levofloxacin in human soft tissue infections. Br J Clin Pharmacol 2004, 57(5):563-8
55. Tomaselli F, Maier A, Matzi V, et al. Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis. Antimicrob Agents Chemother 2004;48(6):2228-32
56. Presant CA, Wolf W, Waluch V, et al. Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet 1994;343(8907):1184-7
57. Chaurasia CS, Muller M, Bashaw ED, et al. AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res 2007;24(5):1014-25 (Pubitemid 46675390)
58. Ungerstedt U. Microdialysis-principles and applications for studies in animals and man. J Intern Med 1991;230(4):365-73
59. de Lange EC, de Boer BA, Breimer DD. Microdialysis for pharmacokinetic analysis of drug transport to the brain. Adv Drug Deliv Rev 1999;36(2-3): 211-27
60. de Lange EC, Danhof M, de Boer AG, Breimer DD. Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res Brain Res Rev 1997;25(1):27-49
61. Brunner M, Derendorf H. Clinical microdialysis: current applications and potential use in drug development. Trends Anal Chem 2006;25(7):674-80
62. Elmquist WF, Sawchuk RJ. Application of microdialysis in pharmacokinetic studies. Pharm Res 1997;14(3):267-88
63. Muller M. Microdialysis in clinical drug delivery studies. Adv Drug Deliv Rev 2000;45(2-3): 255-69
64. de Lange EC, de Vries JD, Zurcher C, et al. The use of intracerebral microdialysis for the determination of pharmacokinetic profiles of anticancer drugs in tumor-bearing rat brain. Pharm Res 1995;12(12):1924-31
65. Konings IR, Engels FK, Sleijfer S, et al. Application of prolonged microdialysis sampling in carboplatin-treated cancer patients. Cancer Chemother Pharmacol 2009;64(3):509-16
66. Zhou Q, Gallo JM. In vivo microdialysis for PK and PD studies of anticancer drugs. AAPS J 2005;7(3):E659-67
67. Loos WJ, Zamboni WC, Engels FK, et al. Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxel. J Pharm Biomed Anal 2007;45(2):288-94
68. Schuck VJ, Rinas I, Derendorf H. In vitro microdialysis sampling of docetaxel. J Pharm Biomed Anal 2004;36(4):807-13
69. Chu J, Gallo JM. Application of microdialysis to characterize drug disposition in tumors. Adv Drug Deliv Rev 2000;45(2-3): 243-53
70. Kehr J. A survey on quantitative microdialysis: theoretical models and practical implications. J Neurosci Methods 1993;48(3):251-61
71. Lonnroth P, Jansson PA, Smith U. A microdialysis method allowing characterization of intercellular water space in humans. Am J Physiol 1987;253(2 Pt 1): E228-31
72. Olson RJ, Justice JB Jr. Quantitative microdialysis under transient conditions. Anal Chem 1993;65(8):1017-22
73. Wang Y, Wong SL, Sawchuk RJ. Microdialysis calibration using retrodialysis and zero-net flux: application to a study of the distribution of zidovudine to rabbit cerebrospinal fluid and thalamus. Pharm Res 1993;10(10):1411-19
74. Carcaboso AM, Elmeliegy MA, Shen J, et al. Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Cancer Res 2010;70(11):4499-508
75. Jacobs S, McCully CL, Murphy RF, et al. Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates. Cancer Chemother Pharmacol 2010;65(5):817-24
76. Sani SN, Henry K, Bohlke M, et al. The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumor-bearing mice: a microdialysis study. Cancer Chemother Pharmacol 2010;66(1):159-69
77. Apparaju SK, Gudelsky GA, Desai PB. Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis. Cancer Chemother Pharmacol 2008;61(2):223-9
78. Zhou Q, Guo P, Kruh GD, et al. Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. Clin Cancer Res 2007;13(14):4271-9
79. Zamboni WC, Gervais AC, Egorin MJ, et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 2004;53(4):329-36
80. Dukic SF, Kaltenbach ML, Heurtaux T, et al. Influence of C6 and CNS1 brain tumors on methotrexate pharmacokinetics in plasma and brain tissue. J Neurooncol 2004;67(1-2): 131-8
81. Johansen MJ, Thapar N, Newman RA, Madden T. Use of microdialysis to study platinum anticancer agent pharmacokinetics in preclinical models. J Exp Ther Oncol 2002;2(3):163-73
82. Ma J, Li S, Reed K, et al. Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. J Pharmacol Exp Ther 2003;305(3):833-9
83. Ma J, Pulfer S, Li S, et al. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res 2001;61(14):5491-8
84. Devineni D, Klein-Szanto A, Gallo JM. Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. Cancer Res 1996;56(9):1983-7
85. Devineni D, Klein-Szanto A, Gallo JM. In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. Cancer Chemother Pharmacol 1996;38(6):499-507
86. Brunner M, Muller M. Microdialysis: an in vivo approach for measuring drug delivery in oncology. Eur J Clin Pharmacol 2002;58(4):227-34
87. Hunz M, Jetter A, Warm M, et al. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. Clin Pharmacol Ther 2007;81(5):659-68
88. Mader RM, Schrolnberger C, Rizovski B, et al. Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. Br J Cancer 2003;88(5):782-7
89. Muller M, Mader RM, Steiner B, et al. 5-Fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients. Cancer Res 1997;57(13):2598-601
90. Joukhadar C, Klein N, Mader RM, et al. Penetration of dacarbazine and its active metabolite 5-aminoimidazole-4-carboxamide into cutaneous metastases of human malignant melanoma. Cancer 2001;92(8):2190-6
91. Tegeder I, Brautigam L, Seegel M, et al. Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer. Clin Pharmacol Ther 2003;73(5):417-26
92. Benveniste H. Brain microdialysis. J Neurochem 1989;52(6):1667-79
93. Salci K, Nilsson P, Howells T, et al. Intracerebral microdialysis and intracranial compliance monitoring of patients with traumatic brain injury. J Clin Monit Comput 2006;20(1):25-31
94. Vespa P, Boonyaputthikul R, McArthur DL, et al. Intensive insulin therapy reduces microdialysis glucose values without altering glucose utilization or improving the lactate/pyruvate ratio after traumatic brain injury. Crit Care Med 2006;34(3):850-6
95. Chan TV, Ng SC, Lam JM, et al. Monitoring of autoregulation using intracerebral microdialysis in patients with severe head injury. Acta Neurochir Suppl 2005;95:113-16
96. Vespa P, Bergsneider M, Hattori N, et al. Metabolic crisis without brain ischemia is common after traumatic brain injury: a combined microdialysis and positron emission tomography study. J Cereb Blood Flow Metab 2005;25(6):763-74
97. Vespa PM, McArthur D, O'Phelan K, et al. Persistently low extracellular glucose correlates with poor outcome 6 months after human traumatic brain injury despite a lack of increased lactate: a microdialysis study. J Cereb Blood Flow Metab 2003;23(7):865-77
98. Goodman JC, Valadka AB, Gopinath SP, et al. Extracellular lactate and glucose alterations in the brain after head injury measured by microdialysis. Crit Care Med 1999;27(9):1965-73
99. Wang E, Ho CL, Lee KK, et al. Changes in brain biochemistry and oxygenation in the zone surrounding primary intracerebral hemorrhage. Acta Neurochir Suppl 2008;102:293-7
100. Miller CM, Vespa PM, McArthur DL, et al. Frameless stereotactic aspiration and thrombolysis of deep intracerebral hemorrhage is associated with reduced levels of extracellular cerebral glutamate and unchanged lactate pyruvate ratios. Neurocrit Care 2007;6(1):22-9
101. Nilsson OG, Polito A, Saveland H, et al. Are primary supratentorial intracerebral hemorrhages surrounded by a biochemical penumbra? A microdialysis study. Neurosurgery 2006;59(3):521-8; discussion 521-8
102. Sarrafzadeh AS, Sakowitz OW, Kiening KL, et al. Bedside microdialysis: a tool to monitor cerebral metabolism in subarachnoid hemorrhage patients? Crit Care Med 2002;30(5):1062-70
103. Kett-White R, Hutchinson PJ, Al-Rawi PG, et al. Adverse cerebral events detected after subarachnoid hemorrhage using brain oxygen and microdialysis probes. Neurosurgery 2002;50(6):1213-21; discussion 1221-2
104. Staub F, Graf R, Gabel P, et al. Multiple interstitial substances measured by microdialysis in patients with subarachnoid hemorrhage. Neurosurgery 2000;47(5):1106-15; discussion 1115-16
105. During MJ, Spencer DD. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 1993;341(8861):1607-10
106. Poca MA, Sahuquillo J, Vilalta A, et al. Percutaneous implantation of cerebral microdialysis catheters by twist-drill craniostomy in neurocritical patients: description of the technique and results of a feasibility study in 97 patients. J Neurotrauma 2006;23(10):1510-17
107. Bergenheim AT, Capala J, Roslin M, Henriksson R. Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study. J Neurooncol 2005;71(3):287-93
108. Benjamin RK, Hochberg FH, Fox E, et al. Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium. Neuro Oncol 2004;6(1):65-74
109. Ruggeri M, Zoli M, Grimaldi R, et al. Aspects of neural plasticity in the central nervous system-III. Methodological studies on the microdialysis technique. Neurochem Int 1990;16(4):427-35 (Pubitemid 20221672)
110. Benveniste H, Diemer NH. Cellular reactions to implantation of a microdialysis tube in the rat hippocampus. Acta Neuropathol 1987;74(3):234-8
111. Lindberger M, Tomson T, Lars S. Microdialysis sampling of carbamazepine, phenytoin and phenobarbital in subcutaneous extracellular fluid and subdural cerebrospinal fluid in humans: an in vitro and in vivo study of adsorption to the sampling device. Pharmacol Toxicol 2002;91(4):158-65
112. Scheyer RD, During MJ, Hochholzer JM, et al. Phenytoin concentrations in the human brain: an in vivo microdialysis study. Epilepsy Res 1994;18(3):227-32
113. Hau P, Fabel K, Baumgart U, et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 2004;100(6):1199-207
114. Mindermann T, Zimmerli W, Gratzl O. Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space. Antimicrob Agents Chemother 1998;42(10):2626-9
115. Dhodapkar M, Rubin J, Reid JM, et al. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 1997;3(7):1093-100
116. Reid JM, Stevens DC, Rubin J, Ames MM. Pharmacokinetics of 3-methyl-(triazen-1-yl) imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin Cancer Res 1997;3(12 Pt 1):2393-8
117. Morgan ME, Singhal D, Anderson BD. Quantitative assessment of blood-brain barrier damage during microdialysis. J Pharmacol Exp Ther 1996;277(2):1167-76
118. Groothuis DR, Ward S, Schlageter KE, et al. Changes in blood-brain barrier permeability associated with insertion of brain cannulas and microdialysis probes. Brain Res 1998;803(1-2): 218-30
119. Terasaki T, Deguchi Y, Kasama Y, et al. Determination of in vivo steady-state unbound drug concentration in the brain interstitial fluid by microdialysis. Int J Pharmaceut 1992;81:143-52
120. Tossman U, Ungerstedt U. Microdialysis in the study of extracellular levels of amino acids in the rat brain. Acta Physiol Scand 1986;128(1):9-14 (Pubitemid 16023701)
121. Marklund N, Blennow K, Zetterberg H, et al. Monitoring of brain interstitial total tau and beta amyloid proteins by microdialysis in patients with traumatic brain injury. J Neurosurg 2009;110(6):1227-37
122. Mellergard P, Aneman O, Sjogren F, et al. Changes in extracellular concentrations of some cytokines, chemokines, and neurotrophic factors after insertion of intracerebral microdialysis catheters in neurosurgical patients. Neurosurgery 2008;62(1):151-7, discussion 157-8
123. Hillman J, Aneman O, Persson M, et al. Variations in the response of interleukins in neurosurgical intensive care patients monitored using intracerebral microdialysis. J Neurosurg 2007;106(5):820-5
124. Waelgaard L, Pharo A, Tonnessen TI, Mollnes TE. Microdialysis for monitoring inflammation: efficient recovery of cytokines and anaphylotoxins provided optimal catheter pore size and fluid velocity conditions. Scand J Immunol 2006;64(3):345-52
125. Clough GF. Microdialysis of large molecules. AAPS J 2005;7(3):E686-92
126. Hillman J, Aneman O, Anderson C, et al. A microdialysis technique for routine measurement of macromolecules in the injured human brain. Neurosurgery 2005;56(6):1264-8, discussion 1268-70
127. Hutchinson PJ, O'Connell MT, Nortje J, et al. Cerebral microdialysis methodology-evaluation of 20 kDa and 100 kDa catheters. Physiol Meas 2005;26(4):423-8
128. Badie B, Chen M, Synold T, Portnow J. Assessment of the peritumoral micro-environment following craniotomy using intracerebral microdialysis [abstract #558]. Neuro Oncol 2009;11(5):690
129. Zhou Q, Gallo JM. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro Oncol 2009;11(3):301-10
130. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733-40
131. Hunz M, Jetter A, Warm M, et al. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. Clin Pharmacol Ther 2007;81(5):659-68
132. Thompson JF, Siebert GA, Anissimov YG, et al. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Br J Cancer 2001;85(2):157-65